Scancell Holdings PLC (LSE:SCLP) Share Price

Company Profile

Business description
Scancell Holdings PLC is a clinical-stage biotechnology company developing treatments for unmet needs in cancer. The Company leverages its ImmunoBody and Moditope platforms to develop targeted, off-the-shelf, patient-accessible active immunotherapies designed to generate safe, potent, and long-lasting tumour-specific immunity. Its product, iSCIB1+, is an ImmunoBody DNA active immunotherapy that has demonstrated monotherapy activity in adjuvant melanoma. The ImmunoBody platform uses DNA-encoded modified antibodies engineered to express epitopes from cancer antigens and target activated antigen-presenting cells in vivo. iSCIB1+ is developed for the treatment of melanoma with checkpoint inhibitors and is administered by needle-free intramuscular injection.
Contact
Sanders Road
Unit 202, Bellhouse Building
Oxford Science Park
OxfordOX4 4GD
GBR
T: +44 1865582066
https://www.scancell.co.uk
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
30 April 2027
Employees
61

Recommended

Near-term pain, long-term potential.

Dan Baker | 22 October 2026

We see the company’s momentum in its core advertising business, as well as adoption of Muse, as early signals that the firm’s AI playbook is working.

Malik Ahmed Khan, CFA | 22 October 2026

Our increased valuation comes from higher full self-driving adoption assumptions and a lower near- and medium-term capital expenditures forecast.

Seth Goldstein, CFA | 22 October 2026

Index	Last price	Change	% Change
All Ordinaries	8,905.80	11.30	-0.13%
CAC 40	7,779.46	31.80	-0.41%
DAX 40	25,314.40	57.35	-0.23%
Dow JONES (US)	52,867.98	11.89	0.02%
FTSE 100	10,693.75	31.28	-0.29%
HKSE	23,093.37	158.69	0.69%
NASDAQ	26,008.86	694.00	-2.60%
Nikkei 225	62,693.16	214.68	-0.34%
NZX 50 Index	13,733.93	12.91	-0.09%
S&P 500	7,663.43	93.74	-1.21%
S&P/ASX 200	8,795.20	2.00	0.02%
SSE Composite Index	3,690.48	32.45	0.89%